Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
Shares of several vaccine makers including Pfizer and Astrazeneca were down Friday morning following the nomination of Robert ...
Finbold | Finance in Bold3h
Shot Down: Vaccine stocks tumble with RFK Jr. as Health Secretary
The immediate aftermath of the nomination saw vaccine stock prices drop on account of Kennedy’s well-publicized views on ...
This is the One Reason Moderna, Novavax, and Drug Stocks Slumped
Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect Trump said that ...
RFK Jr. would rattle health markets as head of HHS, but his confirmation is far from certain, analyst says
Robert F. Kennedy Jr. would create "significantly more volatility" in health markets if he is confirmed as Secretary of Health and Human Services, making navigating policy risks far more challenging, ...
BioNTech SE’s Strategic Growth in Oncology and mRNA
BioNTech SE (BNTX) has released an update. BioNTech SE is entering a new phase of growth, focusing on expanding its oncology ...
FiercePharma6h
Fierce Pharma Asia—Merck and BioNTech's I-O bispecific buys; AZ CEO's China defense
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
poandpo.com8h
BioNTech buys China’s Biotheus in $800 million push into cancer drugs
BioNTech SE and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage ...
Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
Shares of BioNTech (BNTX) and Novavax (NVAX) closed with losses of 7%, while Moderna's stock (MRNA) shed 6%. Vaxcyte (PCVX) dropped 4%, and Pfizer (PFE) pulled back 3%. The sizeable declines in these ...
MM&M1d
BioNTech spends $800M upfront to pick up China-based Biotheus
BioNTech is investing in a promising space in oncology by acquiring Biotheus’ PD-L1 and VEGF bispecific antibody.
Business Insider1d
BioNTech to acquire Biotheus for upfront consideration of $800M
BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel ...
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...